ArticleWorld journal of urology2026
Bladder preservation vs. radical cystectomy for T2N0M0: trends and survival outcomes from SEER.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare treatment trends and survival between bladder‑preserving (BP) therapy and radical cystectomy (RC) in patients with T2N0M0 muscle‑invasive bladder cancer (MIBC) using a large population‑based cohort.
methodsThis retrospective cohort study used the Surveillance, Epidemiology, and End Results (SEER) database (2010‑2022) to identify 10,495 patients with T2N0M0 MIBC. Temporal trends in treatment modalities (RC, trimodality therapy [TMT], partial cystectomy with chemotherapy [PC + CT], etc.) were analyzed. The primary outcomes were overall survival (OS) and cancer‑specific mortality (CSM). Propensity score matching (PSM) was used to compare OS and CSM between treatment groups. Fine‑Gray competing risk regression generated cumulative incidence curves and estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for CSM. Kaplan‑Meier estimation with log‑rank tests and multivariable Cox regression were also performed. All comparative survival results are reported with complete 95% CIs to quantify statistical uncertainty and avoid overinterpretation of non-significant findings.
resultsFrom 2010 to 2022, the use of multimodal therapy increased. Specifically, TMT rose from 11.9% to 26.2%, and RC + CT increased from 8.9% to 23.9%, while monotherapies declined. After PSM, RC demonstrated superior 5-year OS compared to TMT (62.6% vs. 36.7%, p < 0.001). Notably, PC + CT showed no statistically significant 5-year survival differences relative to RC (OS: p = 0.893,HR = 0.97,95%CI(0.59-1.58); CSM: p = 0.902,HR = 1.04,95%CI(0.55-1.94)). Chemotherapy significantly improved survival for patients undergoing transurethral resection of bladder tumor (TURBT) and PC, but not RC. Multivariable analysis confirmed older age, female sex, and higher T-stage as risk factors, while chemotherapy and surgery (RC/PC) were protective.
conclusionThis study reveals a significant shift towards multimodal therapy for T2N0M0 MIBC. Although RC remains associated with the best overall survival, PC + CT showed no statistically significant difference in OS or CSM compared with RC, supporting its potential as a BP option for carefully selected patients. Nevertheless, these findings are constrained by the limited sample size of the PC + CT cohort, the absence of functional and quality-of-life outcomes, and residual confounding inherent in the SEER database. The inferior survival of TMT in real-world practice underscores the critical importance of stringent patient selection for bladder preservation strategies.
Indexed as
Identifiers
42606609What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.